MedTrace Logo

Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment

NCT03289234 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2026-05-22

Study results available
· View outcomes & findings →

Summary

To assess the pharmacokinetics of MCI-186 after a single intravenous infusion of 30mg/hour in subjects with mild or moderate Hepatic impairment compared to subjects with normal hepatic function

Conditions

  • Hepatic Impairment
  • Healthy

Interventions

DRUG

MCI-186

30 mg of edaravone will be administered intravenously over 60 minutes

Sponsors & Collaborators

  • Tanabe Pharma Corporation

    lead INDUSTRY

Principal Investigators

  • General Manager · Tanabe Pharma Corporation

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-11-16
Primary Completion
2018-07-20
Completion
2018-07-24

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03289234 on ClinicalTrials.gov